|Bid||24.29 x 1000|
|Ask||24.38 x 1300|
|Day's range||23.80 - 26.40|
|52-week range||9.53 - 70.29|
|Beta (5Y monthly)||1.77|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.
Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.
ChemoCentryx, Inc. ( NASDAQ:CCXI ) is possibly approaching a major achievement in its business, so we would like to...